Literature DB >> 23111236

Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.

Nao Saito1, Naoya Yoshioka, Riichiro Abe, Hongjiang Qiao, Yasuyuki Fujita, Daichi Hoshina, Asuka Suto, Satoru Kase, Nobuyoshi Kitaichi, Michitaka Ozaki, Hiroshi Shimizu.   

Abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions caused by drugs or infections and exhibiting widespread epidermal necrosis. Currently, there is no animal model that reproduces SJS/TEN symptoms.
OBJECTIVE: We sought to develop a novel mouse model of SJS/TEN by using PBMCs and skin from patients who had recovered from SJS/TEN.
METHODS: For our mouse model, patients' PBMCs were injected intravenously into immunocompromised NOD/Shi-scid, IL-2Rγ(null) (NOG) mice, followed by oral administration of a causative drug. Subsequently, to replace human skin, unaffected skin specimens obtained from patients who had recovered from SJS/TEN were grafted onto NOG mice, after which patient-derived PBMCs and the causative drug were applied.
RESULTS: Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion and numerous cell death of conjunctival epithelium, whereas there were no symptoms in mice injected with PBMCs from patients with ordinary drug skin reactions. CD8(+) T lymphocyte-depleted PBMCs from patients with SJS/TEN did not elicit these symptoms. In addition, skin-grafted mice showed darkening of the skin-grafted areas. Cleaved caspase-3 staining showed that dead keratinocytes were more numerous in the skin-grafted mice than in the healthy control animals.
CONCLUSION: We have established a novel human-oriented SJS/TEN mouse model and proved the importance of CD8(+) T lymphocytes in SJS/TEN pathogenesis. The mouse model promises to promote diagnostic and therapeutic approaches.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23111236     DOI: 10.1016/j.jaci.2012.09.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

Review 1.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

Review 2.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

3.  Identification of drug-specific public TCR driving severe cutaneous adverse reactions.

Authors:  Ren-You Pan; Mu-Tzu Chu; Chuang-Wei Wang; Yun-Shien Lee; Francois Lemonnier; Aaron W Michels; Ryan Schutte; David A Ostrov; Chun-Bing Chen; Elizabeth Jane Phillips; Simon Alexander Mallal; Maja Mockenhaupt; Teresa Bellón; Wichittra Tassaneeyakul; Katie D White; Jean-Claude Roujeau; Wen-Hung Chung; Shuen-Iu Hung
Journal:  Nat Commun       Date:  2019-08-08       Impact factor: 14.919

4.  Therapeutic Effects of Mesenchymal Stem Cells on a Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Model.

Authors:  So Young Park; In Young Oh; Jung Hyun Kim; Hyo Jung Kim; Bomi Seo; Oh Young Kwon; Woo Jung Song; Hyouk Soo Kwon; You Sook Cho; Hee Bom Moon; Tae Bum Kim
Journal:  J Korean Med Sci       Date:  2020-04-20       Impact factor: 2.153

5.  Severe Cutaneous Adverse Reaction (SCAR): Clinical Pharmacologists' Viewpoint.

Authors:  Nusrat Shafiq; Samiksha Bhattacharjee; Samir Malhotra
Journal:  Indian Dermatol Online J       Date:  2022-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.